Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vaxcyte Inc. Common Stock (PCVX) vs Philip Morris International Inc. (PM) Price & Performance

Vaxcyte Inc. Common StockTrade
Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

Vaxcyte Inc. Common Stock vs Philip Morris International Inc. — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Philip Morris International Inc. trades at $207.74 (market cap $310.62B). The key difference: Philip Morris International Inc. is far larger — about 29.6× Vaxcyte Inc. Common Stock's market cap, and Philip Morris International Inc. pays a 3.21% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Philip Morris International Inc. for 85 Days on average.

PCVXPM
Market Cap
$10.51B$310.62B
Volume
2,644,6944,145,126
Sector
HealthConsumer Staples
52-Week High
$73.82$205.58
52-Week Low
$40.32$144.33
Typical Hold Time
0 Days85 Days
Enterprise Value
$9.14B$353.73B
Dividend Yield
—3.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vaxcyte Inc. Common Stock

No Aura AI signal available yet.

Philip Morris International Inc.

Philip Morris International (PM) trades at $202.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $212.17. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.20, and maintains robust profitability with a net income margin of 25.56%. Recent news highlights growth in smoke-free products like IQOS and ZYN, now over 40% of revenue, and a raised 2026 EPS forecast due to favorable currency impacts.

The stock offers a compelling growth story driven by smoke-free product expansion and dividend reliability, but faces risks from regulatory pressures and high valuation multiples. With 68% of analysts rating it a Buy, upside exists toward the $225 high target, though investors should monitor debt levels and industry shifts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PCVX
100% Buy0% Sell
Avg holding period · 0 Days
PM
32% Buy68% Sell
Avg holding period · 85 Days

Top news

Latest headlines on both assets

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM →